Treatment of disseminated non-seminomatous testicular cancer: The european experience

Seminars in Surgical Oncology

Volumn 17, Issue 4, 1999, Pages 250-256

  De Wit, Ronald ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Bleomycin; Bone marrow transplantation; Carboplatin; Cisplatin; Clinical trials; Combined antineoplastic agents; Cyclophosphamide; Disease free survival; Drug administration schedule; Drug dose response relationship; Etoposide; Germ cell and embryonal neoplasms; Granulocyte colony stimulating factor; Hematopoietic stem cell transplantation; Ifosfamide; Neoplasm staging; Paclitaxel; Phase I clinical trials; Phase II clinical trials; Prognosis; Risk factors; Salvage therapy; Survival rate; Testicular neoplasms; Vinbla stine; Vincristine

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; METHOTREXATE; VINBLASTINE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DISSEMINATED CANCER; DRUG EFFICACY; EUROPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TESTIS CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; EUROPE; GERMINOMA; HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 0032763862     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199912)17:4<250::AID-SSU5>3.0.CO;2-M     Document Type: Review

References (32)

1. Einhorn LH: Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1981;41:3275-3280.
2. Einhorn LH: Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990;8:1777-1781.
3. Bajorin D, Katz A, Chan E, et al: Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. J Clin Oncol 1988;6:786-792.
4. Mead GM, Stenning SP, Parkinson MC, et al: The second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumours. Medical Research Council Testicular Tumour Working Party [published erratum appears in J Clin Oncol 1992;10:867]. J Clin Oncol 1992;10:85-94.
5. Mead GM, Stenning SP: Prognostic factors for metastatic germ cell cancer treated with platinum-based chemotherapy: the International Germ Cell Cancer Collaborative Group (IGCCCG) project to standardise risk criteria [Abstract]. Proc Am Soc Clin Oncol 1994; 13:251.
6. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. New Engl J Med 1987;316:1435-1440.
7. de Wit R, Stoter G, Kaye SB, et al: Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997;15:1837-1843.
8. Levi JA, Raghaven D, Harvey V, et al: The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol 1993; 11:1300-1305.
9. Loehrer PJ Sr, Johnson D, Elson P, et al: Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995;13:470-476.
10. Horwich A, Sleijfer D, Fossa S, et al: A trial of carboplatin-based combination chemotherapy in good prognosis metastatic testicular non-seminoma [Abstract]. Proc Am Soc Clin Oncol 1994;13:231. Abstract #709.
11. Einhorn LH, Williams SD, Loehrer PJ, et al: Evaluation of optimal duration of chemotherapy in favorable prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989;7:387-391.
12. de Wit R, Roberts JT, Wilkinson P, et al: Is 3BEP equivalent to 3BEP-1EP in good prognosis germ cell cancer? An EORTC-MRC phase III study [Abstract]. J Clin Oncol 1999;18:309a.
13. Bajorin DF, Bosl GP: Bleomycin in germ cell tumor therapy: not all regimens are created equal [editorial]. J Clin Oncol 1997;15:1717-1719.
14. Goldie JH, Coldman AJ, Gudauskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982;66:439-449.
15. Goldie JH, Coldman AJ: The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984;44:3643-3653.
16. Hitchins RN, Newlands ES, Smith DB, et al: Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis. Br J Cancer 1989;59:236-242.
17. Cullen MH, Harper PG, Woodroffe CM, et al: Chemotherapy for poor risk germ cell tumours. An independent evaluation of the POMB/ACE regime. Br J Urol 1988;62:454-460.
18. Wit de R, Stoter G, Sleijfer DT, et al: Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma: a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 1995;71:1311-1314.
19. Nichols CR, Williams SD, Loehrer PJ, et al: Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991;9:1163-1172.
20. Loehrer PJ Sr, Einhorn LH, Williams SD: VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 1986;4:528-536.
21. Nichols CR., Catalano PJ, Crawford ED, et al: Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998;16:1287-1293.
22. Wit de R, Stoter G, Sleijfer DT, et al: Four cycles of BEP vs. four cycles of VIP in patients with intermediate-prognosis metastatic nonseminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 1998;78:828-832.
23. Kaye SB, Mead GM, Fossa S, et al: Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998;16:692-701.
24. Fossa SD, Kaye SB, Mead GM, et al: Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998;16:716-724.
25. Motzer RJ, Bajorin DF, Schwartz LH, et al: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994;12:2277-2283.
26. Bokemeyer C, Beyer J, Metzner B, et al: Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996;7:31-40.
27. de Wit R, Louwerens M, de Mulder PH, et al: Management of intermediate prognosis germ cell cancer; results of a phase I/II study of Taxol-BEP. Int J Cancer. In press.
28. Nichols CR, Tricot G, Williams SD, et al: Dose-intensive chemotherapy in refractory germ cell cancer - a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989;7:932-939.
29. Broun ER, Nichols CR, Turns M, et al: Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 1994;73:1716-1720.
30. Motzer RJ, Mazumdar M, Gulati SC, et al: Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993;85:1828-1835.
31. Chevreau C, Droz JP, Pico JL, et al: Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Eur Urol 1993; 23:213-218.
32. Bokemeyer C, Harstrick A, Beyer J, et al: The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group [Review]. Semin Oncol 1998;25:24-32.